May 8, 2020 / 9:55 PM / a month ago

BRIEF-Tonix Pharmaceuticals - U.S. FDA Informed Co That Breakthrough Therapy Designation Was Rescinded For Tnx-102 Sl For Post-Traumatic Stress Disorder Treatment

May 8 (Reuters) - Tonix Pharmaceuticals Holding Corp :

* TONIX PHARMACEUTICALS - U.S. FDA INFORMED CO THAT BREAKTHROUGH THERAPY DESIGNATION WAS RESCINDED FOR TNX-102 SL FOR POST-TRAUMATIC STRESS DISORDER TREATMENT Source text for Eikon: bit.ly/2L8YrOe Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below